Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS–DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI

Yew, Kuan Leong

doi:10.1016/j.ijcard.2015.02.092

International Journal of Cardiology

2015

DOI: 10.1016/j.ijcard.2015.02.092

|View full text |Cite

Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS–DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI

Kuan Leong Yew

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2018

Publication Types

Select...

Article7

Relationship

Self Cite1

Independent6

Authors

Journals

Cited by 7 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sole use of BVS in long lesions with significantly calcified segments may not be reasonable, especially if lesion preparation was not optimal and might result in significant residual stenosis even after balloon postdilatation. Also, the bifurcation lesion treatment seems to be an interesting indication for using this hybrid approach [4].The aim of the study was to share our current experience in using single BVS in a real life scenario, with special focus on the assessment of safety and effectiveness of the hybrid approach, i.e. the simultaneous use of overlapping stents: BVS and classical DES.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment

et al. 2016

View full text Add to dashboard Cite

A b s t r a c tBackground: The number of percutaneous coronary interventions (PCI) with bioresorbable vascular scaffolds (BVS) is increasing because these procedures offer additional benefits compared to PCI with classical drug eluting stents (DES) made of permanent metallic prostheses.Aim: To present the current experience of using BVS in a real life scenario in patients with stable coronary artery disease (CAD), with a special focus on the assessment of safety and effectiveness of the hybrid strategy (single stage BVS and DES implantation). Methods:We performed a one-arm prospective registry, which enrolled patients with stable CAD in five interventional cardiology centres in Poland. All patients who met inclusion and exclusion criteria and had received at least one BVS stent during index PCI were included. The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE), consisting of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularisation (TLR) at 12 months. The analysis was performed in the whole population as well as in the subgroup with the hybrid treatment (BVS + DES).Results: Between August 2013 and April 2014 139 patients were enrolled. The mean age was 59.5 ± 5.5 years, and 34.5% of the population were women. The target vessel was located in the left anterior descending artery in most cases (65.5%). The device success rate was 100%. At 12 months, in the whole population the cumulative MACE incidence was 7.2% (n = 10), while the clinically-driven TLR rate was 5.0% (n = 7). In further analysis, in the hybrid subgroup there was no death, MI, or stent thrombosis, and only one case of clinically-driven TLR (4.5%). Conclusions:The obtained data enable us to say that in particular clinical scenarios the simultaneous use of BVS and DES might be safe and effective. 628INTRODUCTION Drug-eluting stents (DES) have greatly improved outcomes of percutaneous coronary intervention (PCI) by managing the issue of excessive neointimal growth. However, the permanent presence of the metallic platform and the durable polymer might impair the natural healing process of the coronary vessel wall and lead to a prolonged inflammatory response as well as untoward clinical outcomes [1,2].Recently, PCI with bioresorbable vascular scaffolds (BVS) has emerged as an interesting alternative because the presence of the prosthesis (the scaffold as well as the polymer with the drug) in the coronary artery is temporary. Moreover, this novel technology enables restoration of the normal vessel reactivity and facilitates positive remodelling. As a consequence, it reduces the trigger for persistent inflammation and enables further interventions by percutaneous or surgical means [3].Also, the hybrid use of BVS and classical DES is a novel approach. This strategy can be applied to reduce the costs of PCI for very long lesions but also to avoid certain limitations of currently available Absorb BVS ® stents. The customisation (sizes and lengths) of BVS at the time of the study wa...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…

It is heartening to note that there is viewership and interest in the article "Hybrid ABSORB Bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" [1]. Dr Granata and colleagues had made certain pertinent statements and raised concerns about the hybrid BVS-DES paper [1,2].

…”

mentioning

confidence: 99%

“…Dr Granata and colleagues had made certain pertinent statements and raised concerns about the hybrid BVS-DES paper [1,2]. The valuable comments are much appreciated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Further elucidation on “Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS–DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI”

Yew

2015

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients

Tröbs

Achenbach

Röther

et al. 2016

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS–DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI

Cited by 7 publications

References 9 publications

The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment

The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment

Further elucidation on “Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS–DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI”

Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients

Contact Info

Product

Resources

About